Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B

Novo Nordisk faces growth deceleration concerns, intensified by competitive pressures from Eli Lilly and supply chain issues. NVO can improve buying sentiments by expanding its indications beyond its core weight loss and diabetes categories. NVO's growth-adjusted valuation has improved markedly, while its first-mover advantage should anchor its ability to scale profitably.

Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)

Catalent

Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout

The Wegovy maker's once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.

Novo Nordisk New Pill Reduces Heart Attacks, Strokes in Diabetic Patients

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.

Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study

Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some point during the trial.

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds

Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Weight loss drugs such as Novo Nordisk (NYSE:NVO) AS' Ozempic have been found to cut alcohol and opioid abuse, according to a new study. Published in the journal Addiction, the study showed the rate of opioid overdoses among people taking GLP-1 drugs was 40% lower than those who were not.

Ozempic, weight loss drugs found to cut substance abuse

Eli Lilly

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.

Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?

Novo Nordisk's decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners

Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.

Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

AstraZeneca

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?

AZN or NVO: Which Is the Better Value Stock Right Now?

Plans to roll out weight loss drug Wegovy through the NHS have fallen short of expectations after the treatment's approval late last year. Just 800 patients had received prescriptions of the drug by April, according to Sky News, against Department of Health estimates that 13,500 people would be on Wegovy by then.

Wegovy weight loss drug roll out falling short in the UK

Vertex Pharmaceuticals

These stocks look like slam-dunk picks for growth investors.

3 No-Brainer Growth Stocks to Buy in October

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in the world's most populous nation by beefing up senior leadership in India and partnering with local AI start-ups, a top executive told Reuters.

Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India

U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent , saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs.

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

2 No-Brainer Dividend Growth Stocks to Buy Right Now

Celsius Holdings

Dell Technologies

These stocks are all down 14% or more in the past three months.

Got $5,000? These 3 Growth Stocks Are on Sale Right Now.

Novo Nordisk (NVO) closed the most recent trading day at $117.20, moving -0.48% from the previous trading session.

Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors

Bagsværd, Denmark, 8 October 2024 – Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together with a coalition of partners such as city governments, academic institutions and non-profit organisations, the initiative will support six cities in designing, implementing and evaluating tailored solutions focused on physical activity and healthy eating.

Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities

Bagsværd, Denmark, 7 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

News for Novo Nordisk Stock (NVO)